Related Experiment Video
Updated: Aug 2, 2026
13:04
Generation and Grafting of Tissue-engineered Vessels in a Mouse Model
Published on: March 18, 2015
12.6K
Decellularized vascular matrix material-based TEVG coated with PRP for anti-degradation and anti-inflammation
Shui-Lan Wu1,2,3, Jian-Yi Xu2,3, Xu-Heng Sun3
1Department of Burn and Plastic Surgery, Guangzhou First People's Hospital, Guangzhou, Guangdong, China.
International Journal of Surgery (London, England)
|September 24, 2025
Summary
Platelet-rich plasma (PRP) derivatives, specifically platelet growth factor (PGF), enhance tissue-engineered vascular grafts by reducing immune rejection and implant degradation. This promotes better vascular regeneration and implant longevity in vivo.
Area of Science:
- Biomaterials Science
- Immunology
- Regenerative Medicine
Background:
- Vascular regeneration is linked to inflammation and implant degradation.
- Platelet-rich plasma (PRP) contains cytokines that can mitigate inflammatory responses.
- Autologous PRP shows potential for improving implant biocompatibility.
Purpose of the Study:
- To reduce immune rejection and degradation of implants in vivo.
- To evaluate the efficacy of different Platelet-rich plasma (PRP) derivatives in tissue-engineered vascular grafts (TEVGs).
- To assess the impact of Platelet-rich plasma (PRP) on macrophage polarization and inflammatory markers.
Main Methods:
- Tissue-engineered vascular grafts (TEVGs) were modified with phosphate-buffered saline (PBS), fibrin (FIB), platelet growth factor (PGF), or a PGF blend.
- In vitro and in vivo (rat subcutaneous transplantation) studies were conducted.
- Cytokine release, tissue morphology (H&E, Masson's), macrophage polarization (CD206, CD86), and gene expression were analyzed.
Main Results:
- Platelet growth factor (PGF) and PGF-coated groups increased the M2/M1 macrophage ratio, indicating reduced inflammation.
- Enhanced water absorption capacity and delayed extracellular matrix (ECM) metabolism were observed in PGF-treated implants.
- Platelet-rich plasma (PRP) downregulated inflammation-related genes, effectively reducing the inflammatory response.
Conclusions:
- Platelet growth factor (PGF) and PGF-coated TEVGs significantly reduced immune rejection in vivo.
- These modifications decreased implant degradation by mitigating collagen loss.
- The findings support the use of Platelet-rich plasma (PRP) derivatives to improve vascular graft performance.
